Omalizumab

Details

Files

Generic Name:

Omalizumab

Project Status:

Complete

Therapeutic Area:

Asthma, severe persistent

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Brand Name:

Xolair

Project Line:

Reimbursement Review

Project Number:

SR0045-000

Submission Type:

Resubmission

Indications:

Asthma, severe persistent

Recommendation Type:

Do not list

Final Recommendation:

March 7, 2006

Recommendation:

(tentative)

Files

Submission Status Report View PDF

Recommendation and Reasons View PDF

Last Updated : October 13, 2005